These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 35988535)
1. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases. Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O Oncology; 2022; 100(10):542-554. PubMed ID: 35988535 [TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From Pike LRG; Miao E; Boe LA; Patil T; Imber BS; Myall NJ; Pollom EL; Hui C; Qu V; Langston J; Chiang V; Grant M; Goldberg SB; Palmer JD; Prasad RN; Wang TJC; Lee A; Shu CA; Chen LN; Thomas NJ; Braunstein SE; Kavanagh BD; Camidge DR; Rusthoven CG J Clin Oncol; 2024 Oct; 42(30):3606-3617. PubMed ID: 39047224 [TBL] [Abstract][Full Text] [Related]
3. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978 [TBL] [Abstract][Full Text] [Related]
4. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302 [TBL] [Abstract][Full Text] [Related]
5. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions. Zhang T; Zhang Y; Zhou L; Deng S; Huang M; Liu Y; Liu Y; Gong Y; Zhu J; Xue J; Bai Y; Ma H; Zhang Y; Yu M; Li Y; Wang Y; Zou B; Zhou X; Xiu W; Na F; Xu Y; Peng F; Wang J; Lu Y Cancer Med; 2020 Dec; 9(23):8772-8781. PubMed ID: 33027555 [TBL] [Abstract][Full Text] [Related]
6. Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases. Zerdes I; Kamali C; Koulouris A; Elsayed M; Schnorbach J; Christopoulos P; Tsakonas G ESMO Open; 2023 Dec; 8(6):102069. PubMed ID: 37988952 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy. Zhou Y; Li J; Li Y; Deng G; Wang Q; Qin H; Li J; Li Z Clin Transl Oncol; 2024 Aug; 26(8):1968-1975. PubMed ID: 38478262 [TBL] [Abstract][Full Text] [Related]
8. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459 [TBL] [Abstract][Full Text] [Related]
9. Management and Outcomes of Newly Diagnosed Non-Small Cell Lung Cancer Patients with Brain Metastases: A Real-World Study in Japan. Yoshida H; Kim YH; Iwatsubo S; Sakaguchi C; Sakamori Y; Nagai H; Ozasa H; Mio T; Hirai T Oncology; 2020; 98(7):460-467. PubMed ID: 32222702 [TBL] [Abstract][Full Text] [Related]
10. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746 [TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598 [TBL] [Abstract][Full Text] [Related]
12. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
13. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Yu X; Sheng J; Pan G; Fan Y Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485 [TBL] [Abstract][Full Text] [Related]
14. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases. Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042 [TBL] [Abstract][Full Text] [Related]
15. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
17. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study. Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086 [TBL] [Abstract][Full Text] [Related]
19. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Rangachari D; Yamaguchi N; VanderLaan PA; Folch E; Mahadevan A; Floyd SR; Uhlmann EJ; Wong ET; Dahlberg SE; Huberman MS; Costa DB Lung Cancer; 2015 Apr; 88(1):108-11. PubMed ID: 25682925 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):406-413. PubMed ID: 27598807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]